
    
      This study is an open-label, randomized and crossover study designed to evaluate the effect
      of cyclosporine on the pharmacokinetics of SyB V-1901. Healthy adult subjects will receive an
      IV dose of SyB V-1901 alone, simultaneous administration of SyB V-1901 with cyclosporine, and
      coadministration of cyclosporine at 2 hours after completion of SyB V-1901 infusion. Eligible
      subjects will be randomized to one of two groups, to receive the treatment sequence of
      assigned group.
    
  